Mechanisms and Duration of Immunity to SARS-CoV-2

总体情况：摘要 我们建议斯坦福大学U54 SARS-CoV-2血清学卓越中心(SUS-COE)作为 SeroNet联盟成员齐聚一堂，解决更好地了解人类的迫切需要 对席卷美国和世界的SARS-CoV-2冠状病毒大流行的免疫反应。 我们的中心将建立在四个科学支柱的基础上： 新冠肺炎患者获得性免疫反应的深机制分析 血清学、B细胞和T细胞反应， 血液和粘膜部位免疫反应的分析， 比较感染引起的免疫反应和候选疫苗引起的免疫反应，以及 研究医疗服务不足、代表性不足和高危患者群体 在这些参数范围内，我们将尝试确定导致有效和持久免疫的因素 与SARS-CoV-2感染有关。 我们致力于广泛的协作，快速共享数据和技术知识，灵活地 应对快速变化的大流行，并将研究结果快速转化为CLIA实验室临床 测试和开发新的治疗方法。我们认为这些是最好的前进路线 解决我们对SARS-CoV-2保护性免疫决定因素的理解上的差距，以及 为医生和患者提供有用的工具。

OVERALL: SUMMARY We propose the Stanford U54 SARS-CoV-2 Serological Sciences Center of Excellence (SUSS-COE) as a member of the SeroNet consortium gathered to address the urgent need for better understanding of human immune responses to the SARS-CoV-2 coronavirus pandemic that has engulfed the U.S. and the world. Our Center will be based on four scientific pillars:  Deep mechanistic analysis of the adaptive immune responses of COVID-19 patients, spanning serological, B cell and T cell responses,  Analysis of immune responses in the blood as well as mucosal sites,  Comparing immune responses induced by infection to those induced by candidate vaccines, and  Studying medically underserved, underrepresented and at-risk patient populations Within these parameters, we will attempt to determine the factors that result in effective and durable immunity to SARS-CoV-2 infection. We are dedicated to broad collaboration, rapid sharing of data and technical knowledge, nimbleness in responding to the rapidly changing pandemic, and rapid translation of research findings to CLIA Lab clinical testing and development of new therapeutic approaches. We feel these are the best routes forward for addressing gaps in our understanding of the determinants of protective immunity to SARS-CoV-2, and providing useful tools for physicians and patients.